Testosterone therapy in older men: clinical implications of recent landmark trials.

Testosterone therapy for men with hypogonadism due to identifiable hypothalamic-pituitary-testicular (HPT) pathology is uncontroversial. However, the risks and benefits of testosterone for men with clinical features of hypogonadism in the absence of identifiable HPT axis pathology have been uncertain. Recent landmark placebo-controlled trials assessed the benefits and risks of testosterone therapy (≤ 3 years) for middle aged and older men with symptoms and possible signs of hypogonadism or end-organ androgen deficiency, low or low-normal serum testosterone concentrations, but no HPT pathology: testosterone therapy 1) had modest-but clinically significant-benefits on average self-reported energy and mood, sexual function and satisfaction; 2) in conjunction with a lifestyle program, reversed or reduced incident diabetes mellitus type 2 (T2D) in men at high risk of or newly diagnosed with T2D; 3) modestly improved objectively assessed muscle strength and timed walking distance; 4) increased bone density and strength, but did not reduce falls or typical osteoporotic fractures and surprisingly increased the risk of fractures typically attributable to trauma; and 5) did not significantly increase the risk of myocardial infarction, stroke or prostate cancer. These landmark trials help to inform clinical decision-making about testosterone therapy for men.

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of European Society of Endocrinology.